JAK2 and myeloproliferative neoplasm: Although limited in scope and testing patients with diverse HLA-I genotype, we obtained evidence for the presence of specific T cells for neoantigens derived from CALRmut and JAK2 V617F mutant peptides in healthy individuals but not in either subgroup of MPN patients.